Literature DB >> 12123845

Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease.

Peggy Nazé1, Isabelle Vuillaume, Alain Destée, Florence Pasquier, Bernard Sablonnière.   

Abstract

Huntington's disease (HD) is attributed to a triplet CAG repeat mutation, and about 70% of the variance in age-at-onset can be explained by the size of the repeat expansion. Among potential candidates as modifier genes, we investigated the role of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene. We examined the association of HD with the I93M mutation and S18Y polymorphism in 138 HD patients and 136 control subjects, but we did not identify the I93M mutation. The S18Y polymorphism was present in 17% of HD patients. Of the variance in the age-at-onset that was not accounted for by the CAG repeat, 13% could be attributed to S18Y polymorphism. We sequenced the entire coding region of the UCH-L1 gene in seven HD patients with unexplained older or younger onset age. The S18Y polymorphism was found in three out of the four patients presenting with a later age-at-onset. We conclude that the UCH-L1 gene may be a genetic factor that influences the variability in age-at-onset of HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12123845     DOI: 10.1016/s0304-3940(02)00231-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  29 in total

1.  TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Authors:  Ji-Hyun Lee; Jong-Min Lee; Eliana Marisa Ramos; Tammy Gillis; Jayalakshmi S Mysore; Shotaro Kishikawa; Tiffany Hadzi; Audrey E Hendricks; Michael R Hayden; Patrick J Morrison; Martha Nance; Christopher A Ross; Russell L Margolis; Ferdinando Squitieri; Cinzia Gellera; Estrella Gomez-Tortosa; Carmen Ayuso; Oksana Suchowersky; Ronald J Trent; Elizabeth McCusker; Andrea Novelletto; Marina Frontali; Randi Jones; Tetsuo Ashizawa; Samuel Frank; Marie-Helene Saint-Hilaire; Steven M Hersch; Herminia D Rosas; Diane Lucente; Madaline B Harrison; Andrea Zanko; Ruth K Abramson; Karen Marder; Jorge Sequeiros; G Bernhard Landwehrmeyer; Ira Shoulson; Richard H Myers; Marcy E MacDonald; James F Gusella
Journal:  Biochem Biophys Res Commun       Date:  2012-07-03       Impact factor: 3.575

2.  Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.

Authors:  J M Andresen; J Gayán; S S Cherny; D Brocklebank; G Alkorta-Aranburu; E A Addis; L R Cardon; D E Housman; N S Wexler
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

3.  Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Authors:  Zhihua Liu; Robin K Meray; Tom N Grammatopoulos; Ross A Fredenburg; Mark R Cookson; Yichin Liu; Todd Logan; Peter T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

Review 4.  Deubiquitylating enzymes in neuronal health and disease.

Authors:  Fatima Amer-Sarsour; Alina Kordonsky; Yevgeny Berdichevsky; Gali Prag; Avraham Ashkenazi
Journal:  Cell Death Dis       Date:  2021-01-22       Impact factor: 8.469

5.  A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.

Authors:  Kristina Bečanović; Anne Nørremølle; Scott J Neal; Chris Kay; Jennifer A Collins; David Arenillas; Tobias Lilja; Giulia Gaudenzi; Shiana Manoharan; Crystal N Doty; Jessalyn Beck; Nayana Lahiri; Elodie Portales-Casamar; Simon C Warby; Colúm Connolly; Rebecca A G De Souza; Sarah J Tabrizi; Ola Hermanson; Douglas R Langbehn; Michael R Hayden; Wyeth W Wasserman; Blair R Leavitt
Journal:  Nat Neurosci       Date:  2015-05-04       Impact factor: 24.884

6.  The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease.

Authors:  Silke Metzger; Peter Bauer; Juergen Tomiuk; Franco Laccone; Stefano Didonato; Cinzia Gellera; Paola Soliveri; Herwig W Lange; Helga Weirich-Schwaiger; Gregor K Wenning; Bela Melegh; Victoria Havasi; Lazlo Balikó; Stefan Wieczorek; Larissa Arning; Jacek Zaremba; Anna Sulek; Dorota Hoffman-Zacharska; A Nazli Basak; Nagehan Ersoy; Jana Zidovska; Vera Kebrdlova; Massimo Pandolfo; Pascale Ribaï; Ludovit Kadasi; Marta Kvasnicova; Bernhard H F Weber; Friedmar Kreuz; Matthias Dose; Manfred Stuhrmann; Olaf Riess
Journal:  Neurogenetics       Date:  2005-12-21       Impact factor: 2.660

7.  Genome-wide In Vivo CNS Screening Identifies Genes that Modify CNS Neuronal Survival and mHTT Toxicity.

Authors:  Mary H Wertz; Mollie R Mitchem; S Sebastian Pineda; Lea J Hachigian; Hyeseung Lee; Vanessa Lau; Alex Powers; Ruth Kulicke; Gurrein K Madan; Medina Colic; Martine Therrien; Amanda Vernon; Victoria F Beja-Glasser; Mudra Hegde; Fan Gao; Manolis Kellis; Traver Hart; John G Doench; Myriam Heiman
Journal:  Neuron       Date:  2020-01-30       Impact factor: 17.173

8.  Evaluation of blastomere biopsy using a mouse model indicates the potential high risk of neurodegenerative disorders in the offspring.

Authors:  Yang Yu; Jindao Wu; Yong Fan; Zhuo Lv; Xuejiang Guo; Chun Zhao; Rong Zhou; Zhuo Zhang; Fuqiang Wang; Min Xiao; Ling Chen; Hui Zhu; Wen Chen; Min Lin; Jiayin Liu; Zuomin Zhou; Liu Wang; Ran Huo; Qi Zhou; Jiahao Sha
Journal:  Mol Cell Proteomics       Date:  2009-03-11       Impact factor: 5.911

9.  Huntington's disease: the case for genetic modifiers.

Authors:  James F Gusella; Marcy E MacDonald
Journal:  Genome Med       Date:  2009-08-21       Impact factor: 11.117

Review 10.  Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis.

Authors:  Margaret Ragland; Carolyn Hutter; Cyrus Zabetian; Karen Edwards
Journal:  Am J Epidemiol       Date:  2009-10-28       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.